Platform Expansion (e.g., C. Diff)

About GIVAX

GIVAX is an early-stage biotech company pioneering a novel oral vaccine platform based on engineered rotavirus vectors. Its core technology repurposes the established safety and mucosal immunogenicity of existing rotavirus vaccines to express antigens from other GI pathogens, starting with norovirus. The company's lead programs target a significant unmet need in pediatric and adult populations, with the potential to address a multi-billion dollar global disease burden. GIVAX is privately held and appears to be in the pre-clinical or early research stage of development.

Therapeutic Areas